Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma

Lipika Goyal; Aparna Govindan; Rahul A. Sheth; Valentina Nardi; Lawrence S. Blaszkowsky; Jason E. Faris; Jeffrey W. Clark; David P. Ryan; Eunice L. Kwak; Jill N. Allen; Janet E. Murphy; Supriya K. Saha; Theodore S. Hong; Jennifer Y. Wo; Cristina R. Ferrone; Kenneth K. Tanabe; Dawn Q. Chong; Vikram Deshpande; Darrell R. Borger; A. John Iafrate; Nabeel Bardeesy; Hui Zheng; Andrew X. Zhu

doi:10.1634/theoncologist.2015-0210

Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma

Lipika Goyal, Aparna Govindan, Rahul A. Sheth, Valentina Nardi, Lawrence S. Blaszkowsky, Jason E. Faris, Jeffrey W. Clark, David P. Ryan, Eunice L. Kwak, Jill N. Allen, Janet E. Murphy, Supriya K. Saha, Theodore S. Hong, Jennifer Y. Wo, Cristina R. Ferrone, Kenneth K. Tanabe, Dawn Q. Chong, Vikram Deshpande, Darrell R. Borger, A. John IafrateNabeel Bardeesy, Hui Zheng, Andrew X. Zhu

Research output: Contribution to journal › Article › peer-review

108 Scopus citations

Abstract

Background. Conflicting data exist regarding the prognostic impact of the isocitrate dehydrogenase (IDH) mutation in intrahepatic cholangiocarcinoma (ICC), and limited data exist in patients with advanced-stage disease. Similarly, the clinical phenotype of patients with advanced IDH mutant (IDHm) ICC has not been characterized. In this study, we report the correlation of IDH mutation status with prognosis and clinicopathologic features in patients with advanced ICC. Methods. Patients with histologically confirmed advanced ICC who underwent tumor mutational profiling as a routine part of their care between 2009 and 2014 were evaluated. Clinical and pathological data were collected by retrospective chart review for patients with IDHm versus IDH wild-type (IDHwt) ICC. Pretreatment tumor volume was calculated on computed tomography or magnetic resonance imaging. Results. Of the 104 patients with ICC who were evaluated, 30 (28.8%) had an IDH mutation (25.0% IDH1, 3.8% IDH2). The median overall survival did not differ significantly between IDHm and IDHwt patients (15.0 vs. 20.1 months, respectively; p 5.17). The pretreatment serum carbohydrate antigen 19-9 (CA19-9) level in IDHm and IDHwt patients was 34.5 and 118.0 U/mL, respectively (p 5.04) Age at diagnosis, sex, histologic grade, and pattern of metastasis did not differ significantly by IDH mutation status. Conclusion. The IDH mutation was not associated with prognosis in patients with advanced ICC. The clinical phenotypes of advanced IDHm and IDHwt ICC were similar, but patients with IDHm ICC had a lower median serum CA19-9 level at presentation.

Original language	English
Pages (from-to)	1019-1027
Number of pages	9
Journal	Oncologist
Volume	20
Issue number	9
DOIs	https://doi.org/10.1634/theoncologist.2015-0210
State	Published - 5 Aug 2015
Externally published	Yes

Keywords

Cholangiocarcinoma
Isocitrate dehydrogenase
Metastatic
Phenotype
Prognosis

Access to Document

10.1634/theoncologist.2015-0210

Cite this

Goyal, L., Govindan, A., Sheth, R. A., Nardi, V., Blaszkowsky, L. S., Faris, J. E., Clark, J. W., Ryan, D. P., Kwak, E. L., Allen, J. N., Murphy, J. E., Saha, S. K., Hong, T. S., Wo, J. Y., Ferrone, C. R., Tanabe, K. K., Chong, D. Q., Deshpande, V., Borger, D. R., ... Zhu, A. X. (2015). Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma. Oncologist, 20(9), 1019-1027. https://doi.org/10.1634/theoncologist.2015-0210

@article{7972c3eca1f449978c83f5b20add86f8,

title = "Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma",

abstract = "Background. Conflicting data exist regarding the prognostic impact of the isocitrate dehydrogenase (IDH) mutation in intrahepatic cholangiocarcinoma (ICC), and limited data exist in patients with advanced-stage disease. Similarly, the clinical phenotype of patients with advanced IDH mutant (IDHm) ICC has not been characterized. In this study, we report the correlation of IDH mutation status with prognosis and clinicopathologic features in patients with advanced ICC. Methods. Patients with histologically confirmed advanced ICC who underwent tumor mutational profiling as a routine part of their care between 2009 and 2014 were evaluated. Clinical and pathological data were collected by retrospective chart review for patients with IDHm versus IDH wild-type (IDHwt) ICC. Pretreatment tumor volume was calculated on computed tomography or magnetic resonance imaging. Results. Of the 104 patients with ICC who were evaluated, 30 (28.8%) had an IDH mutation (25.0% IDH1, 3.8% IDH2). The median overall survival did not differ significantly between IDHm and IDHwt patients (15.0 vs. 20.1 months, respectively; p 5.17). The pretreatment serum carbohydrate antigen 19-9 (CA19-9) level in IDHm and IDHwt patients was 34.5 and 118.0 U/mL, respectively (p 5.04) Age at diagnosis, sex, histologic grade, and pattern of metastasis did not differ significantly by IDH mutation status. Conclusion. The IDH mutation was not associated with prognosis in patients with advanced ICC. The clinical phenotypes of advanced IDHm and IDHwt ICC were similar, but patients with IDHm ICC had a lower median serum CA19-9 level at presentation.",

keywords = "Cholangiocarcinoma, Isocitrate dehydrogenase, Metastatic, Phenotype, Prognosis",

author = "Lipika Goyal and Aparna Govindan and Sheth, {Rahul A.} and Valentina Nardi and Blaszkowsky, {Lawrence S.} and Faris, {Jason E.} and Clark, {Jeffrey W.} and Ryan, {David P.} and Kwak, {Eunice L.} and Allen, {Jill N.} and Murphy, {Janet E.} and Saha, {Supriya K.} and Hong, {Theodore S.} and Wo, {Jennifer Y.} and Ferrone, {Cristina R.} and Tanabe, {Kenneth K.} and Chong, {Dawn Q.} and Vikram Deshpande and Borger, {Darrell R.} and Iafrate, {A. John} and Nabeel Bardeesy and Hui Zheng and Zhu, {Andrew X.}",

note = "Publisher Copyright: {\textcopyright} Alpha Med Press 2015.",

year = "2015",

month = aug,

day = "5",

doi = "10.1634/theoncologist.2015-0210",

language = "English",

volume = "20",

pages = "1019--1027",

journal = "Oncologist",

issn = "1083-7159",

publisher = "Oxford University Press",

number = "9",

}

Goyal, L, Govindan, A, Sheth, RA, Nardi, V, Blaszkowsky, LS, Faris, JE, Clark, JW, Ryan, DP, Kwak, EL, Allen, JN, Murphy, JE, Saha, SK, Hong, TS, Wo, JY, Ferrone, CR, Tanabe, KK, Chong, DQ, Deshpande, V, Borger, DR, Iafrate, AJ, Bardeesy, N, Zheng, H & Zhu, AX 2015, 'Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma', Oncologist, vol. 20, no. 9, pp. 1019-1027. https://doi.org/10.1634/theoncologist.2015-0210

TY - JOUR

T1 - Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma

AU - Goyal, Lipika

AU - Govindan, Aparna

AU - Sheth, Rahul A.

AU - Nardi, Valentina

AU - Blaszkowsky, Lawrence S.

AU - Faris, Jason E.

AU - Clark, Jeffrey W.

AU - Ryan, David P.

AU - Kwak, Eunice L.

AU - Allen, Jill N.

AU - Murphy, Janet E.

AU - Saha, Supriya K.

AU - Hong, Theodore S.

AU - Wo, Jennifer Y.

AU - Ferrone, Cristina R.

AU - Tanabe, Kenneth K.

AU - Chong, Dawn Q.

AU - Deshpande, Vikram

AU - Borger, Darrell R.

AU - Iafrate, A. John

AU - Bardeesy, Nabeel

AU - Zheng, Hui

AU - Zhu, Andrew X.

PY - 2015/8/5

Y1 - 2015/8/5

N2 - Background. Conflicting data exist regarding the prognostic impact of the isocitrate dehydrogenase (IDH) mutation in intrahepatic cholangiocarcinoma (ICC), and limited data exist in patients with advanced-stage disease. Similarly, the clinical phenotype of patients with advanced IDH mutant (IDHm) ICC has not been characterized. In this study, we report the correlation of IDH mutation status with prognosis and clinicopathologic features in patients with advanced ICC. Methods. Patients with histologically confirmed advanced ICC who underwent tumor mutational profiling as a routine part of their care between 2009 and 2014 were evaluated. Clinical and pathological data were collected by retrospective chart review for patients with IDHm versus IDH wild-type (IDHwt) ICC. Pretreatment tumor volume was calculated on computed tomography or magnetic resonance imaging. Results. Of the 104 patients with ICC who were evaluated, 30 (28.8%) had an IDH mutation (25.0% IDH1, 3.8% IDH2). The median overall survival did not differ significantly between IDHm and IDHwt patients (15.0 vs. 20.1 months, respectively; p 5.17). The pretreatment serum carbohydrate antigen 19-9 (CA19-9) level in IDHm and IDHwt patients was 34.5 and 118.0 U/mL, respectively (p 5.04) Age at diagnosis, sex, histologic grade, and pattern of metastasis did not differ significantly by IDH mutation status. Conclusion. The IDH mutation was not associated with prognosis in patients with advanced ICC. The clinical phenotypes of advanced IDHm and IDHwt ICC were similar, but patients with IDHm ICC had a lower median serum CA19-9 level at presentation.

AB - Background. Conflicting data exist regarding the prognostic impact of the isocitrate dehydrogenase (IDH) mutation in intrahepatic cholangiocarcinoma (ICC), and limited data exist in patients with advanced-stage disease. Similarly, the clinical phenotype of patients with advanced IDH mutant (IDHm) ICC has not been characterized. In this study, we report the correlation of IDH mutation status with prognosis and clinicopathologic features in patients with advanced ICC. Methods. Patients with histologically confirmed advanced ICC who underwent tumor mutational profiling as a routine part of their care between 2009 and 2014 were evaluated. Clinical and pathological data were collected by retrospective chart review for patients with IDHm versus IDH wild-type (IDHwt) ICC. Pretreatment tumor volume was calculated on computed tomography or magnetic resonance imaging. Results. Of the 104 patients with ICC who were evaluated, 30 (28.8%) had an IDH mutation (25.0% IDH1, 3.8% IDH2). The median overall survival did not differ significantly between IDHm and IDHwt patients (15.0 vs. 20.1 months, respectively; p 5.17). The pretreatment serum carbohydrate antigen 19-9 (CA19-9) level in IDHm and IDHwt patients was 34.5 and 118.0 U/mL, respectively (p 5.04) Age at diagnosis, sex, histologic grade, and pattern of metastasis did not differ significantly by IDH mutation status. Conclusion. The IDH mutation was not associated with prognosis in patients with advanced ICC. The clinical phenotypes of advanced IDHm and IDHwt ICC were similar, but patients with IDHm ICC had a lower median serum CA19-9 level at presentation.

KW - Cholangiocarcinoma

KW - Isocitrate dehydrogenase

KW - Metastatic

KW - Phenotype

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84940656195&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2015-0210

DO - 10.1634/theoncologist.2015-0210

M3 - Article

C2 - 26245674

AN - SCOPUS:84940656195

SN - 1083-7159

VL - 20

SP - 1019

EP - 1027

JO - Oncologist

JF - Oncologist

IS - 9

ER -

Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma

Abstract

Keywords

Access to Document

Fingerprint

Cite this